Gelonghui February 20 丨Huadong Pharmaceutical (000963.SZ) was surveyed on-site by institutions at 14:30-16:00 on February 15, 2023; 11:00-11:40 and 14:00-15:00 on February 16, said that Sinclair's current medical and aesthetic revenue mainly comes from Ellansé®, New high-end hyaluronic acid from the MailI series, Lanluma®Core injectable products such as collagen stimulants, and energy source equipment products such as CoolTech Define from its subsidiary HighTech and Viora's V series are also in a period of rapid growth. Sinclair overcame the impact of rising operating costs and labor costs caused by overseas inflation last year. Overall operations continued to improve, and profit conditions gradually improved. It is expected to achieve good growth this year as well.
Huadong Pharmaceutical (000963.SZ): Sinclair is also expected to achieve good growth this year
This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.